Excess aldosterone is associated with increased cardiovascular risk. Aldosterone has a permissive effect on vascular fibrosis. Cardiovascular magnetic resonance imaging (CMR) allows study of vascular function by measuring aortic distensibility. We compared aortic distensibility in primary aldosteronism (PA), essential hypertension (EH) and normal controls and explored the relationship between aortic distensibility and pulse wave velocity (PWV). We studied PA (n ¼ 14) and EH (n ¼ 33) subjects and agematched healthy controls (n ¼ 17) with CMR, including measurement of aortic distensibility, and measured PWV using applanation tonometry. At recruitment, PA and EH patients had similar blood pressure and left ventricular mass. Subjects with PA had significantly lower aortic distensibility and higher PWV compared with EH and healthy controls. These changes were independent of other factors associated with reduced aortic distensibility, including ageing. There was a significant relationship between increasing aortic stiffness and age in keeping with physical and vascular ageing. As expected, aortic distensibility and PWV were closely correlated. These results demonstrate that PA patients display increased arterial stiffness compared with EH, independent of vascular ageing. The implication is that aldosterone invokes functional impairment of arterial function. The long-term implications of arterial stiffening in aldosterone excess require further study.
INTRODUCTION
The prevalence of primary aldosteronism (PA) is higher than previously thought. Aldosterone excess is found in B10% of unselected hypertensives and up to 20% of subjects with resistant hypertension. 1, 2 It is known that PA patients are at increased cardiovascular risk in comparison with subjects with essential hypertension (EH) and equivalent blood pressure, including dramatic increases in risk of cerebrovascular disease, myocardial infarction and prevalence of atrial fibrillation. 3 These observations and others suggest that aldosterone excess has significant adverse cardiovascular effects beyond its influence on blood pressure. 4, 5 One potential mechanism linking aldosterone and cardiovascular disease relates to arterial stiffness; in vitro data suggest that aldosterone stimulates hyperplasia of vascular smooth muscle cells and additionally activates protein synthesis, increasing extracellular matrix and collagen deposition, leading to vascular fibrosis. [6] [7] [8] Patients with PA have been demonstrated to have increased carotid intima media thickness at ultrasound compared with EH, suggesting that aldosterone excess contributes to fibrosis and thickening of the arterial wall. 9 In addition, aldosterone has also been shown to adversely affect endothelial function by enhancing oxidative stress and inflammation. 10, 11 The potential sequelae of these effects include increasing vascular stiffness and atherosclerosis, which may impede conduit arterial function and worsen cardiovascular outcome.
Epidemiological studies have shown that increased arterial stiffness, most commonly assessed by measurement of pulse wave velocity (PWV), is independently associated with cardiovascular risk factors and morbidity. 12, 13 PWV, measured using applanation tonometry, is the 'gold-standard' technique of arterial stiffness assessment in human subjects, although alternative methods have emerged. 14 A number of studies have demonstrated increased arterial stiffness or impaired arterial conduit function in PA patients compared with EH, using PWV or augmentation index (AIx), respectively, measured with applanation tonometry. 15, 16 Cardiovascular magnetic resonance imaging (CMR) permits visualisation of large arteries and potentially offers an integrated noninvasive method of assessing vascular as well as ventricular function during the same examination. Aortic distensibility (AD) is an index of arterial stiffness and can be defined as the relative change in the cross-sectional area of the aorta divided by central pulse pressure. AD measured with CMR has emerged as a marker of vascular function in groups at elevated cardiovascular risk. 17, 18 CMR allows direct visualisation of blood vessels and is independent of crude estimates of aortic length from tape measurements along the body surface, which are required for PWV assessment with tonometry. CMR also allows vascular assessment in subjects where tonometry may be challenging such as obese subjects.
To date, however, the relationship between AD, measured with CMR, and PWV has not been assessed in PA patients or compared with EH subjects. Thus, we assessed the relationship between CMR measures of vascular function, PWV, AIx and conventional CV risk factors in recently diagnosed PA with EH patients and healthy 1 controls. To give insight into the mechanistic basis for any observed differences, we also measured markers of inflammation and oxidative stress in the PA and EH groups. We hypothesised that PA subjects would exhibit a more adverse vascular phenotype in comparison with EH subjects using CMR.
MATERIALS AND METHODS Subjects
A total of 14 patients with confirmed PA diagnosed in the Endocrine Department, Western Infirmary, Glasgow, were studied. All were diagnosed with PA using Endocrine Society guidelines. 19 Briefly, screened subjects with an elevated aldosterone-to-renin ratio (4750 with aldosterone in pmol l À 1 and renin measured as plasma renin activity in ng ml À 1 per h; 435 if renin measured as plasma renin concentration in mIU ml À 1 ) underwent repeat screening after withdrawal of all treatment affecting measurements of plasma renin and aldosterone (for 4-6 weeks). If the elevated aldosterone-to-renin ratio persisted, then autonomous aldosterone excess was confirmed using a saline suppression test. In this test, PA is confirmed if plasma aldosterone is 4270 pmol l À 1 despite infusion of 2 litres of normal saline over 4 h. Subjects subsequently underwent adrenal imaging (computerised tomography or magnetic resonance imaging) and adrenal vein sampling if surgery was to be considered in order to differentiate between unilateral and bilateral forms of PA.
Two control groups were studied. The first group comprised 33 patients with EH. All patients with EH had a normal aldosterone-to-renin ratio and none were on mineralocorticoid receptor (MR) antagonists. No patient had pre-existing structural cardiac abnormalities (excluded by clinical examination and echocardiography where appropriate). All subjects were outpatients with no intercurrent illness at the time of study. A cohort of 17 healthy volunteers with no past medical history and on no regular medication was also studied. This study was approved by the West of Scotland Research Ethics Committee and all subjects gave informed consent.
CMR technique
All patients underwent CMR using a 1.5 Tesla MRI scanner (Sonata, Siemens, Erlangen, Germany). A fast imaging with steady-state precession sequence was used to acquire cine images of the left ventricle (LV) in long axis followed by sequential short-axis LV cine loops (8 mm slice thickness, 2 mm gap between slices) from the atrioventicular ring to the apex. Imaging parameters, which were standardised for all subjects, included: TR/TE/flip angle/voxel size/FoV ¼ 3.14 ms/1.6 ms/601/2.2 Â 1.3 Â 8.0 mm/340 mm.
AD was assessed from cine MR images in the transverse plane of the ascending aorta obtained at the level of the main pulmonary artery ( Figure 1 ) utilising a fast imaging with steady-state precession sequence (TR ¼ 3.2 ms, TE ¼ 1.6 ms, flip angle ¼ 601, FoV 276 Â 340 mm, pixel dimensions 2.3 Â 1.3 mm, slice thickness ¼ 7 mm). The B10 s breathhold CMR sequence resulted in prospective images with a temporal resolution of at least 22.5 ms. During image acquisition, blood pressure was measured in the CMR scanner using a nonferromagnetic brachial artery sphygmomanometer cuff (Schiller instruments, Baar, Switzerland).
LV mass was analysed by short-axis cine loops using tracing of epicardial and endocardial end-systolic and end-diastolic contours with LV mass calculated using analysis software (Argus, Siemens, Erlangen, Germany) and normalised to body surface area. AD was calculated as previously described from change in aortic volume and simultaneous brachial blood pressure acquired during the scan using the formula: 20, 21 Aortic A schematic illustration of the contour tracing the cross-sectional aortic volume is shown in Figure 1 . All CMR scans were anonymised with a code number before analyses performed by two observers (PBM and SB) blinded to the clinical characteristics of the subjects.
Applanation tonometry measurement of PWV
Measurements of PWV and AIx were carried out after 15 min of rest in the supine position using the SphygmoCor Vx system (Atcor Medical, Sydney, Australia). PWV was measured from sequentially recorded electrocardiogram-gated carotid, femoral artery waveforms. Timing of the pulse wave was using the intersecting tangent algorithm with carotid-femoral pathway measured using the distance obtained by subtracting the carotid measurement site to sternal notch distance from the sternal notch to femoral measurement site distance. PWV measurements were made in triplicate, and the mean values were used in the subsequent analysis. AIx, a measure of wave reflection, was determined from radial waveforms using the same device and corrected to heart rate of 75 beats per min. A trained nurse (blinded to the clinical characteristics of the subjects) performed tonometry measurements.
Blood sampling
Venepuncture was performed in the PA and EH subjects for routine biochemistry on the day of scanning and analysed in the standard clinical laboratories at the Western infirmary, Glasgow. C-reactive protein was measured in a single run on all samples using a high-sensitivity method on a clinically validated automated platform (c311, Roche Diagnostics, Burgess Hill, UK). The analyser was calibrated and quality controlled using the manufacturer's reagents, and according to their instructions. Coefficient of variation of the quality control was o5%. Plasma aldosterone was measured by direct radioimmunoassay utilising the 'Coat-A-Count' system (Euro/DPC Ltd, Caernarfon, Wales, UK). The radioisotope used was 125 I aldosterone. Coefficients of variation (%, within-batch and between-batch, respectively) were 2.3-5.4/3.8-15.7.
Oxidative stress status was assessed by analysing superoxide release from whole blood using an established method. 22, 23 In brief, venous blood was collected in lithium heparinate-containing tubes, kept on ice and processed within half an hour. Superoxide levels were detected by electron paramagnetic resonance (e-scan R; Bruker BioSpin GmbH, Rheinstetten, Germany) with the spin probe 1-hydroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine (CPH; Noxygen, Elzach, Germany) to a final concentration of 500 mM. Instrument settings were: centre field of 3375 G, modulation amplitude of 2.27 G, sweep time of 5.24 s, sweep width of 60 G and 10 scans. Superoxide levels were recorded as counts per min for 10 min and a best fit regression line through these data points was constructed; the calculated slope of this line was used to measure the rate of superoxide anion production.
Power calculation
Based on our previous CMR studies of AD, if the true difference in the experimental and control means is 3 Â 10 À 3 mm Hg À 1 , 12 PA subjects and 24 EH controls are required to detect a significant difference between PA patients and EH patients with power of 0.8 and type I error of 0.05.
Statistical methods
Differences between groups were tested by w 2 or Fisher's exact test and appropriate for categorical variables and by Student's t-test and MannWhitney U-test for continuous variables. Correlations between cardiac Figure 1 . Schematic diagram of the cross-sectional aortic area being defined (volume is calculated by multiplication by the CMR slice thickness). AA, ascending aorta; DA, descending aorta.
dimensions, measures of arterial function and continuous clinical variables were assessed with the Pearson and Spearman correlation coefficients. Analysis of covariance was used to assess influence of covariates on differences in AD between groups, using AD as the dependent variable. All analyses were performed using the SPSS 19.0 software package (IBM, Armonk, NY, USA). Graphs were created using Minitab 15 (Minitab, State College, PA, USA).
RESULTS

Patient demographics, therapy and clinical variables
Patient demographics and the various measures of vascular function are shown in Table 1 . There were no significant differences in age, gender or other clinical variables between the groups. The PA patients were older than the EH patients and controls but this did not reach statistical significance (PA vs EH P ¼ 0.258; PA vs controls P ¼ 0.077). Blood pressure was numerically but not significantly higher in the PA groups compared with EH. Predictably, the healthy control group had a significantly lower body mass index, systolic, diastolic and pulse pressure compared with both the PA and EH subjects. As expected, PA subjects had significantly higher plasma aldosterone and lower serum potassium levels than EH but there was no difference between plasma C-reactive protein or whole blood superoxide production between the groups. As the lab changed assays from plasma renin activity to plasma renin concentration during the study, data on renin levels are not presented.
There were no significant difference in use of angiotensinconverting enzyme inhibitors, angiotensin receptor antagonists, b-blockers or calcium channel antagonists at the time of study between the PA and EH subjects. No PA patients were receiving thiazide diuretics, which were used in 21 (63.6%) of EH patients. Of the 14 PA patients, 4 were on no specific therapy at the time of study, 9 patients were receiving MR antagonists (7 on spironolactone and 2 on eplerenone) and 1 patient had undergone adrenalectomy 7 months before study. In patients on MR antagonists, the median duration of therapy was 180 days (range 28-360 days). Therefore, all PA subjects included in the study were investigated either before, or within 1 year, of either adrenalectomy or commencing specific medical therapy.
LV dimensions and function There were no significant differences between LV mass between PA and EH patients or controls, although LV mass was slightly higher in patients compared with controls. However, PA patients did have smaller LV end-diastolic volume compared with both EH patients and controls. No group had evidence of LV systolic dysfunction. In fact, PA patients had significantly higher LV ejection fraction than either EH patients or controls ( Table 2) .
Measures of vascular function AD was significantly lower in both PA and EH compared with healthy controls (Po0.001), with AD additionally being significantly lower in PA compared with EH subjects despite similar ages and blood pressures in the groups (Table 2 and Figure 2 ). There was a significant negative correlation between age and AD in the whole cohort of patients (R ¼ À 0.454, Po0.001; Figure 3 ). Both markers of increased aortic stiffness correlated with increasing body mass index (AD: R ¼ À 0.277 and P ¼ 0.028; PWV: R ¼ 0.295 and P ¼ 0.022). There were no significant correlations between AD and plasma aldosterone levels, any lipid parameter, C-reactive protein, interleukin-6, superoxide, calcium or phosphate. There were no significant differences in AD between genders in PA or EH groups, although AD was lower in male healthy controls compared with females (mean AD 3.9 Â 10 À 3 vs 5.2 Â 10 À 3 , P ¼ 0.055) despite similar blood pressures. However, the number of females in the PA and EH groups was small. Heart rate-corrected central AIx was significantly lower in the healthy controls compared with EH patients, with a trend towards being lower in PA patients. There was no significant difference in AIx between PA and EH subjects and there did not appear to be any significant relationship between AIx and any clinical variables other than blood pressure. Analysis of covariance performed to assess the differences in AD, as the dependent variable, between the groups, independent of age as a covariate, confirmed significantly lower AD in PA and EH patients compared with controls as a reference. In addition, this demonstrated that for every increase in age by 1 year, AD reduces by 6.75 Â 10 À 5 Hg À 1 , irrespective of the effect of patient group (Table 3) . In contrast, PA subjects have a reduction of 1.0 Â 10 À 3 Hg À 1 compared with PH patients; therefore essentially, PA conveys an excess equivalent of 14.8-year additional ageing compared with EH with comparable blood pressure. Figure 4 illustrates that PWV was significantly higher in both PA and EH compared with controls (Po0.001), with PWV additionally being significantly higher in PA compared with EH subjects (P ¼ 0.001).
Relationship between measures of vascular function As would be expected for complementary methods of assessment of vascular function, there was a significant correlation between AD and PWV (R À 0.433, Po0.001; Figure 5 ). There were also significant correlations between most blood pressure variables and both AD and PWV. The Spearman correlation coefficients for AD and blood pressure variables were as follows: systolic blood pressure (R ¼ À 0.533, Po0.001), diastolic blood pressure (R ¼ À 0.230, P ¼ 0.067) and pulse pressure (R ¼ À 0.540, Po0.001). The Spearman correlation coefficients for PWV and blood pressure variables were as follows: systolic blood pressure (R ¼ 0.317, P ¼ 0.013), diastolic blood pressure (R ¼ 0.297, P ¼ 0.02) and pulse pressure (R ¼ 0.245, P ¼ 0.057). AIx correlated significantly with AD (Spearman's R ¼ À 0.378, P ¼ 0.002), systolic blood pressure (R ¼ 0.426, Po0.001) and pulse pressure (R ¼ 0.407, P ¼ 0.001) but not diastolic blood pressure or PWV. 
DISCUSSION
In this study, PA is associated with increased aortic stiffness manifest as reduced AD and higher pulse wave velocity compared with both healthy controls and subjects with EH. This finding persists after adjustment for age, the other significant predictor of AD. These findings offer further insights into the mechanisms involved in blood pressure-independent increased cardiovascular risk associated with aldosterone excess. Importantly, this is the first study to use CMR to assess AD in PA subjects, although this well-validated technique has been used to explore vascular morbidity in other populations at increased cardiovascular risk. 17, 18 Our findings that PWV is increased in PA subjects compared with EH and normotensive cohorts confirm findings of other similar studies. 15, 24 Central PWV is an established method for assessment of central arterial compliance, with higher PWV being a marker of stiffer central vessels. In vitro and animal studies have demonstrated that aldosterone-mediated MR activation leads directly to vascular smooth muscle cell proliferation and excess collagen deposition, resulting in vascular remodelling and fibrosis. 10, 11 In addition, longer-term clinical studies have demonstrated that amelioration of aldosterone excess either by adrenalectomy or MR blockade reduces PWV as well as carotid intima medial thickness (a surrogate marker of atherosclerosis) at 1 year following treatment. 16, 25 In addition to the observation that AD is reduced in PA subjects compared with other groups, a significant correlation was observed between AD and both age and PWV. The correlation between AD and age across the groups reflects increasing severity of arteriosclerosis with age that persists irrespective of the study group. 26 The observed correlation between PWV and AD (as well as the correlation between AD and AIx) to an extent demonstrates a validation of both techniques as measures of arterial stiffness.
There were no differences in LV masses between the groups (all of which were in the normal range) despite suboptimal blood pressure control in both the PA and EH patients. We were very surprised not to find higher LV mass in the PA population particularly compared with healthy controls, although the mean LV mass in controls was a little lower. This probably reflects the fact that participants had been screened to exclude significant cardiac abnormalities before participation. This may reflect relatively 'mild' hypertension demonstrated by the PA patients in this study as some patients had commenced specific therapy, which may have already begun to induce regression of LV hypertrophy. The implication from our results is that impairment of vascular function occurs earlier in the course of PA, before the onset of LV hypertrophy as end-organ damage and may regress more slowly. In addition, most other studies of LV dimensions in PA and hypertensive patients rely on echocardiography data; CMR provides a more sensitive method of structural analysis and it is unclear how well CMR and echocardiographic findings correlate. In one previous study, LV hypertrophy using CMR was found in only 83 of 440 subjects (18%) with preidentified LV hypertrophy using echocardiography. 27 It is also significant that in the only other study using relating aldosterone status with CMR findings, there was no significant difference in LV mass index between EH subjects with high versus low aldosterone production. 28 The higher LV ejection fraction and smaller LV end-systolic volume in the PA group is intriguing and contrasts with a recent echocardiographic study, which showed the reverse with larger LV end-systolic and end-diastolic volumes in PA patients. 29 We speculate that in our study, the small-end systolic volume may lead to impaired LV filling and may be a risk factor for diastolic dysfunction and/or heart failure with preserved ejection fraction. We were surprised that there were no differences in oxidative stress or C-reactive protein between groups, although this may simply reflect the relatively small size of the groups as excess aldosterone has been associated with both oxidative stress and inflammation. 30 AD has been utilised in several other patient groups as either a marker of increased vascular risk or for identifying patients at risk of poorer long-term cardiovascular survival. 21 In otherwise healthy young individuals, obese subjects have been shown by CMR to have decreased aortic compliance. 31 We observed a significant correlation between increasing body mass index and reduced AD and PWV in our cohort. AD has been demonstrated to be reduced in heart failure, 18 ischaemic heart disease, end-stage renal disease 17 and diabetes. 32 AD may represent a surrogate marker for clinical trials and has been shown to improve following significant weight loss in obese subjects. 33 Interestingly, in patients with chronic kidney disease, the addition of spironolactone to conventional antihypertensive therapy improved AD significantly compared with placebo, hinting at the beneficial effects of MR antagonism on the vasculature in a non-PA patient cohort. 34 Our study has some limitations. As a cross-sectional study, our study demonstrates an association between increased PA and increased arterial stiffness and do not imply causation. The size of the overall cohort is relatively small, as is each of the individual subgroups. Despite our aim to match the hypertensive groups, blood pressure was higher in the PA group, which may have some bearing on the results of vascular function studies. Despite our attempts to match the groups as much as possible for factors that may influence AD (age, renal function, body mass index), with this small study it is possible that other unrecognised factors may influence AD across the groups. Measurement of brachial rather than central blood pressure is a potential issue when using AD as a marker of vascular stiffness. Calculation of AD is based on cross-sectional volume of the vessel wall and pulse pressure. For practical reasons, direct aortic blood pressure measurement has been substituted by noninvasive indirect brachial blood pressure measurement. Therefore, it is difficult to dissociate any clinical effect associated with changes in AD from that due directly to pulse pressure. Nonetheless, as it is otherwise impossible to truly assess aortic stiffness, without documentation of pressure within the vessel lumen, the approach used in this study has been used widely in other patient groups. Finally, although CMR is becoming an increasing widely used technique, it remains expensive and time consuming, and currently remains established as a research tool rather than as routine clinical measure of vascular health. The major advantage of using CMR over other imaging modalities is its ability to provide comprehensive assessment of the vasculature and detailed analysis of myocardial tissue composition in patients at elevated cardiovascular risk in one examination without the use of ionising radiation. 35 Progress is still required to facilitate more rapid scanning and analysis at lower cost. Better automated analysis software should facilitate straightforward assessment of the acquired images.
In summary, these results demonstrate that PA patients demonstrate increased arterial stiffness compared with comparable degrees of EH, independent of normal vascular ageing. This has been illustrated using both applanation tonometry and, uniquely, by assessment of AD using CMR. The implication is that aldosterone per se rather than subsequent hypertension invokes arterial remodelling by direct effects on vascular smooth muscle cells, leading to functional impairment of arterial conduit function. Both CMR and PWV are potential surrogate markers of vascular health that may represent targets for clinical trials of interventions in PA patients. The long-term prognostic implications of increased arterial stiffening in association with aldosterone excess require further study.
